Xiaoyu Zhang Chemical biology and therapeutics

Research Interests

The majority of the human proteome is considered intractable to conventional drug discovery efforts. Our lab seeks to develop small molecule therapeutic modalities that modulate disease pathways or targets in different ways from conventional occupancy-driven small molecule therapies. Our interdisciplinary research program integrates proteomics, biochemistry, cell biology and organic synthesis, and is currently focused on new drug modalities, cancer neoantigens, E3 ubiquitin ligases, and functional proteomics.

Selected Publications

Expanding the landscape of E3 ligases for targeted protein degradation. Kramer LT and Zhang X. Current Research in Chemical Biology. 2022 January 29;2:100020.

DCAF11 Supports Targeted Protein Degradation by Electrophilic Proteolysis-Targeting Chimeras. Zhang X, Luukkonen LM, Eissler CL, Crowley VM, Yamashita Y, Schafroth MA, Kikuchi S, Weinstein DS, Symons KT, Nordin BE, Rodriguez JL, Wucherpfennig TG, Bauer LG, Dix MM, Stamos D, Kinsella TM, Simon GM, Baltgalvis KA, and Cravatt BF. Journal of the American Chemical Society. 2021 April 7;143(13):5141-5149.

SPIN4 Is a Principal Endogenous Substrate of the E3 Ubiquitin Ligase DCAF16. Zhang X, Thielert M, Li H, and Cravatt BF. Biochemistry. 2021 March 9;60(9):637-642.

Chemical Proteomics for Expanding the Druggability of Human Disease. Zhang X. ChemBioChem. 2020 December 1;21(23):3319-3320.

Electrophilic PROTACs that degrade nuclear proteins by engaging DCAF16. Zhang X, Crowley VM, Wucherpfennig TG, Dix MM, and Cravatt BF. Nature Chemical Biology. 2019 July;15(7):737-746.

View all publications by Xiaoyu Zhang in the National Library of Medicine (PubMed).